TherapeuticsMD stock slips 1.49% and underperforms in positive session

4 articles · Updated · MarketWatch · May 8

Shares closed at $1.98 on Friday as the Nasdaq rose 1.71% to 26,247.08 and the Dow edged up 0.02% to 49,609.16.
The decline marked TherapeuticsMD's third straight daily loss, leaving the stock 32.88% below its 52-week high of $2.95 reached on 27 January.
TherapeuticsMD also lagged AbbVie, whose shares fell 0.57% to $201.55, while trading volume jumped to 59,541, above its 50-day average of 22,353.

Is TherapeuticsMD's royalty-only model a cautionary tale for struggling drug companies or a path to survival?

Can a high-stakes lawsuit against its main partner reverse TherapeuticsMD's slide toward insolvency?

With women's health booming, why is a company with approved products facing potential collapse?